Publication date: Dec 30, 2024
Background: During the acute phase of COVID-19, a number of immunological abnormalities have been reported, but few studies longitudinally analyzed the specific subsets of peripheral blood lymphocytes. Methods: In this observational, prospective, and longitudinal study, adult patients developing acute pneumonia during the COVID-19 pandemic have been followed up for 12 months. Peripheral blood lymphocyte subsets were assessed (with a specific focus on the memory markers) at 6 time points after the disease onset until 12 months. Results: A total of 76 patients with acute pneumonia (characterized by a prevalently interstitial pattern of lung inflammation) at the hospital admission (who completed the 12-month follow-up period) were recruited in this study. They were divided into two groups, namely positive (n = 31) and negative (n = 45) patients for the SARS-CoV-2 PCR test. In the acute phase, the general lymphocyte immunophenotyping profile was comparable for most parameters between these groups, except for B cells. When B and T cells were analyzed according to the expression of memory markers, a significant decrease in nacEFve CD8 T cells was observed in the SARS-CoV-2-positive pneumonia group during the acute phase. Notably, this aspect was maintained during the follow-up period for at least 9 months. Conclusions: COVID-19 pneumonia seems to be associated with a lower number of nacEFve CD8 T cells compared to pneumonia patients negative for this virus. This alteration can persist in the convalescent phase.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Pneumonia |
disease | IDO | role |
disease | MESH | COVID-19 |
disease | MESH | abnormalities |
disease | IDO | blood |
disease | MESH | Infectious Diseases |
drug | DRUGBANK | Coenzyme M |
disease | MESH | infections |
disease | MESH | mutation rate |
disease | IDO | host |
disease | MESH | emergency |
disease | MESH | viral infection |
disease | IDO | cell |
disease | MESH | inflammation |
disease | IDO | infection |
disease | MESH | interstitial lung disease |
disease | MESH | HIV infection |
pathway | REACTOME | HIV Infection |
disease | MESH | chronic renal failure |
drug | DRUGBANK | Immune Globulin Human |
disease | IDO | protein |
drug | DRUGBANK | Edetic Acid |
drug | DRUGBANK | Flunarizine |
drug | DRUGBANK | Aspartame |
disease | MESH | diabetes mellitus |
disease | MESH | chronic renal disease |
drug | DRUGBANK | Pentaerythritol tetranitrate |
disease | MESH | Comorbidity |
disease | MESH | Hypertension |
disease | MESH | cardiovascular disease |